DE69738329D1 - Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins - Google Patents

Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins

Info

Publication number
DE69738329D1
DE69738329D1 DE69738329T DE69738329T DE69738329D1 DE 69738329 D1 DE69738329 D1 DE 69738329D1 DE 69738329 T DE69738329 T DE 69738329T DE 69738329 T DE69738329 T DE 69738329T DE 69738329 D1 DE69738329 D1 DE 69738329D1
Authority
DE
Germany
Prior art keywords
anthraxtoxin
testimonies
antigenes
help
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69738329T
Other languages
English (en)
Other versions
DE69738329T2 (de
Inventor
Kurt Klimpel
Theresa J Goletz
Naveen Arora
Stephen H Leppla
Jay A Berzofsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69738329D1 publication Critical patent/DE69738329D1/de
Application granted granted Critical
Publication of DE69738329T2 publication Critical patent/DE69738329T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69738329T 1996-09-17 1997-09-16 Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins Expired - Fee Related DE69738329T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2527096P 1996-09-17 1996-09-17
US25270P 1996-09-17
PCT/US1997/016452 WO1998011914A1 (en) 1996-09-17 1997-09-16 Targeting antigens to the mhc class i processing pathway with anthrax toxin fusion protein

Publications (2)

Publication Number Publication Date
DE69738329D1 true DE69738329D1 (de) 2008-01-10
DE69738329T2 DE69738329T2 (de) 2008-11-27

Family

ID=21825053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738329T Expired - Fee Related DE69738329T2 (de) 1996-09-17 1997-09-16 Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins

Country Status (6)

Country Link
US (3) US6592872B1 (de)
EP (1) EP0957934B1 (de)
AU (1) AU727015B2 (de)
CA (1) CA2265852A1 (de)
DE (1) DE69738329T2 (de)
WO (1) WO1998011914A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
AU785143B2 (en) 2000-02-04 2006-10-05 Beth Israel Deaconess Medical Center Human immunodeficiency virus vaccine
DE60128008T2 (de) * 2000-12-05 2008-01-10 Wisconsin Alumni Research Foundation, Madison Rezeptor für ein toxin aus bacillus anthracis
AU2008203414B2 (en) * 2001-03-28 2012-08-16 General Hospital Corporation Methods of delivery of exogenous proteins to the cytosol and uses thereof
WO2002079417A2 (en) * 2001-03-28 2002-10-10 President And Fellows Of Harvard College Methods of delivery of exogenous proteins to the cytosol and uses thereof
US7282580B2 (en) * 2001-03-29 2007-10-16 Council Of Scientific And Industrial Research Protein molecule useful for inhibition of anthrax toxin
GB2393122B (en) * 2001-06-08 2005-12-28 Avant Immunotherapeutics Inc Improved vaccination against anthrax
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
AU2003256289A1 (en) * 2002-06-26 2004-01-19 Human Genome Sciences, Inc. Modified shine-dalgarno sequences and methods of use thereof
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US20070105799A1 (en) * 2002-09-10 2007-05-10 Vical Incorporated Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
US20060002941A1 (en) * 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
EP1735338B1 (de) * 2004-02-11 2013-04-24 Ligocyte Pharmaceuticals, Inc. Anthrax-antigene und anwendungsverfahren
EP2025762A3 (de) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex-Trackingassay
WO2007145760A2 (en) * 2006-05-12 2007-12-21 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
CA2656606A1 (en) 2006-06-30 2008-09-25 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates,synthesis and uses thereof
US8420607B2 (en) * 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
US20110256172A1 (en) * 2008-10-14 2011-10-20 The Regents Of The University Of Michigan Epitope-targeted anthrax vaccine
US9968666B2 (en) 2009-06-12 2018-05-15 Vaccine Technologies, Incorporated Methods and compositions for promoting a cell-mediated immune response
CN102549425A (zh) 2009-06-12 2012-07-04 疫苗技术公司 用于测量细胞介导的免疫应答的诊断试验所用的方法和组合物
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
EP2663337A4 (de) 2011-01-10 2014-06-11 Harvard College Verfahren zur abgabe von mitteln in zellen mittels bakterieller toxine
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
AU2012255132B2 (en) * 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
AU2013222334A1 (en) 2012-02-23 2014-09-11 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
EP2928476B1 (de) 2012-12-07 2018-02-14 GlycoMimetics, Inc. Verbindungen, zusammensetzungen und verfahren mit e-selectin-antagonisten zur mobilisierung blutbildender zellen
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
HUE045542T2 (hu) 2014-12-03 2019-12-30 Glycomimetics Inc E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
AU2017341065B2 (en) 2016-10-07 2023-04-06 Glycomimetics, Inc. Highly potent multimeric E-selectin antagonists
EP3596096A1 (de) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7455064B2 (ja) 2018-03-05 2024-03-25 グリコミメティクス， インコーポレイテッド 急性骨髄性白血病および関連状態を処置する方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676068B1 (fr) 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
CA2077277A1 (en) * 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
US5591631A (en) 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
CA2239909A1 (en) 1995-12-13 1997-07-03 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for the delivering compounds into cells

Also Published As

Publication number Publication date
DE69738329T2 (de) 2008-11-27
US20030198651A1 (en) 2003-10-23
US7097965B2 (en) 2006-08-29
EP0957934B1 (de) 2007-11-28
AU727015B2 (en) 2000-11-30
EP0957934A1 (de) 1999-11-24
US20020048590A1 (en) 2002-04-25
AU4352197A (en) 1998-04-14
CA2265852A1 (en) 1998-03-26
US6592872B1 (en) 2003-07-15
WO1998011914A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
DE69738329D1 (de) Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins
DE69526751D1 (de) Multiprozessorsystem zur lokalen Verwaltung von Adressenübersetzungstabellen
NO933878D0 (no) Ultrasonisk behandlingssystem
DK91192D0 (da) Protein
DE69703813D1 (de) System zur expression von heterologen antigenen als fusionsproteine
ITTO950140A0 (it) Procedimento e sistema di aferesi
DK0807198T3 (da) Sammenføjningssystem
BG97200A (bg) Заместени бензимидазоли,метод за получаването им и тяхното фармацевтично приложение
NO941296L (no) Flytende rengjöringspreparat
DK19991D0 (da) Proteinpraeparationer
DE59507556D1 (de) Selbstvernetzende wässrige Zubereitungen von Perfluoralkylgruppen enthaltenden Harzen
DE69427690T2 (de) Verbesserungen im auftrennen von proteinen
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE69111436D1 (de) Zusammensetzungen von flüssigen, milden geschirrspülmitteln.
BR9103099A (pt) Sistema de xampu
FR2693776B1 (fr) Joint homocinetique.
DK132892D0 (da) Proteiner
DE69428892D1 (de) Micropartikel verwendbar als ultraschallkontrastmittel
TR28045A (tr) Partikül formundaki selüloz-esasli maddenin filtreden gecirilmesi.
ITTO930555A0 (it) Giunto idrodinamico
BR9606951A (pt) Proteinas matantes
DE69522582T2 (de) NEUE VERWENDUNGEN VON INDOLO-[2,3b]-CHINOXALINEN
FI933426A0 (fi) Liitos
DE59504988D1 (de) Niedrigviskose wässrige konzentrate von betaintensiden
EE9700247A (et) Pestitsiidpreparaadid ja protsess nende valmistamiseks

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee